Context Therapeutics修订协议，彻底免除CT-202未来里程碑付款与特许权使用费义务

美股速递05-18

Context Therapeutics Inc.宣布，已成功修订其关于药物CT-202的许可协议。根据修订条款，公司未来所有与此药物相关的里程碑付款及特许权使用费义务均被完全免除。此项调整显著优化了公司的财务结构，移除了潜在的长期现金流支出，为未来的研发与运营提供了更大的财务灵活性。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1144105280?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-18 18:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144105280","market":"us","top_or_hot":-1,"title":"Context Therapeutics修订协议，彻底免除CT-202未来里程碑付款与特许权使用费义务","media":"美股速递","content":"<p>Context Therapeutics Inc.宣布，已成功修订其关于药物CT-202的许可协议。根据修订条款，公司未来所有与此药物相关的里程碑付款及特许权使用费义务均被完全免除。此项调整显著优化了公司的财务结构，移除了潜在的长期现金流支出，为未来的研发与运营提供了更大的财务灵活性。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Context Therapeutics修订协议，彻底免除CT-202未来里程碑付款与特许权使用费义务</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nContext Therapeutics修订协议，彻底免除CT-202未来里程碑付款与特许权使用费义务\n</h2>\n\n<h4 class=\"meta\">\n\n2026-05-18 18:47 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Context Therapeutics Inc.宣布，已成功修订其关于药物CT-202的许可协议。根据修订条款，公司未来所有与此药物相关的里程碑付款及特许权使用费义务均被完全免除。此项调整显著优化了公司的财务结构，移除了潜在的长期现金流支出，为未来的研发与运营提供了更大的财务灵活性。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1144105280","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144105280","pubTimestamp":1779101240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Context Therapeutics Inc.宣布，已成功修订其关于药物CT-202的许可协议。根据修订条款，公司未来所有与此药物相关的里程碑付款及特许权使用费义务均被完全免除。此项调整显著优化了公司的财务结构，移除了潜在的长期现金流支出，为未来的研发与运营提供了更大的财务灵活性。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","BCAB":"BioAtla, Inc.","BK4139":"生物科技","CNTX":"Context Therapeutics Inc."},"translate_title":"Context Therapeutics revises agreement to completely waive CT-202 future milestone payment and royalty obligations","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCAB":1,"CNTX":1},"content_text":"Context Therapeutics Inc.宣布，已成功修订其关于药物CT-202的许可协议。根据修订条款，公司未来所有与此药物相关的里程碑付款及特许权使用费义务均被完全免除。此项调整显著优化了公司的财务结构，移除了潜在的长期现金流支出，为未来的研发与运营提供了更大的财务灵活性。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144105280","isCrawlerRequest":true}